DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.…
DiaMedica (DMAC) Q3 2026 Earnings Call Transcript
DiaMedica Therapeutics (NASDAQ: DMAC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 35 employees.
The shares were at 8.250 USD on 20 November 2026, up 39.4% over 52 weeks. Its 52-week range is 5.245 USD to 11.00 USD: the price is 25.0% below the high and 57.3% above the low.
Its market capitalisation is 445.15M USD.
DiaMedica Therapeutics reports return on equity of -58.4% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 34.75M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 4 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 16.25 USD is 97.0% above the current price. The next earnings report is expected on 30 March 2027.